(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
2 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide...
Stats | |
---|---|
आज की मात्रा | 954 600 |
औसत मात्रा | 1.31M |
बाजार मूल्य | 1 434.07B |
EPS | ¥0 ( 2024-02-06 ) |
अगली कमाई की तारीख | ( ¥28.50 ) 2024-05-07 |
Last Dividend | ¥27.00 ( 2023-06-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 24.75 |
ATR14 | ¥0.838 (0.03%) |
मात्रा सहसंबंध
Kyowa Kirin Co., Ltd. सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Kyowa Kirin Co., Ltd. सहसंबंध - मुद्रा/वस्त्र
Kyowa Kirin Co., Ltd. वित्तीय
Annual | 2023 |
राजस्व: | ¥442.23B |
सकल लाभ: | ¥320.62B (72.50 %) |
EPS: | ¥151.03 |
FY | 2023 |
राजस्व: | ¥442.23B |
सकल लाभ: | ¥320.62B (72.50 %) |
EPS: | ¥151.03 |
FY | 2022 |
राजस्व: | ¥398.37B |
सकल लाभ: | ¥311.46B (78.18 %) |
EPS: | ¥99.68 |
FY | 2021 |
राजस्व: | ¥352.25B |
सकल लाभ: | ¥264.40B (75.06 %) |
EPS: | ¥97.20 |
Financial Reports:
No articles found.
Kyowa Kirin Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥27.00 (N/A) |
¥0 (N/A) |
¥27.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥2.50 | 2000-03-28 |
Last Dividend | ¥27.00 | 2023-06-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 49 | -- |
Total Paid Out | ¥539.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.35 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.32 | |
Div. Directional Score | 9.55 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8065.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7337.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6586.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5932.T | Ex Dividend Junior | 2023-11-29 | Annually | 0 | 0.00% | |
4612.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
3839.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3091.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
1961.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9972.T | Ex Dividend Junior | 2023-11-29 | Annually | 0 | 0.00% | |
8963.T | Ex Dividend Junior | 2023-12-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.184 | 1.500 | 6.33 | 9.49 | [0 - 0.5] |
returnOnAssetsTTM | 0.0791 | 1.200 | 7.36 | 8.83 | [0 - 0.3] |
returnOnEquityTTM | 0.101 | 1.500 | 9.99 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.358 | -1.000 | 6.42 | -6.42 | [0 - 1] |
currentRatioTTM | 4.59 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.93 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.03 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0232 | -1.500 | 9.61 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 535.43 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 214.94 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 153.83 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0285 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.742 | 1.000 | 0.962 | 0.962 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.230 | 1.000 | 7.40 | 7.40 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.84 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.431 | 0.800 | -0.460 | -0.368 | [0.5 - 2] |
Total Score | 12.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 17.66 | 1.000 | 8.32 | 0 | [1 - 100] |
returnOnEquityTTM | 0.101 | 2.50 | 9.99 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 153.83 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.10 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 214.94 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.358 | 1.500 | 6.42 | -6.42 | [0 - 1] |
pegRatioTTM | 0.432 | 1.500 | -0.450 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.261 | 1.000 | 5.97 | 0 | [0.1 - 0.5] |
Total Score | 6.32 |
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं